What is Zacks Research's Forecast for BDX FY2027 Earnings?

Becton, Dickinson and Company (NYSE:BDX - Free Report) - Stock analysts at Zacks Research reduced their FY2027 EPS estimates for shares of Becton, Dickinson and Company in a research report issued on Monday, December 16th. Zacks Research analyst R. Department now expects that the medical instruments supplier will post earnings of $16.68 per share for the year, down from their previous estimate of $16.75. The consensus estimate for Becton, Dickinson and Company's current full-year earnings is $14.43 per share.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, beating analysts' consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The business had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the prior year, the company posted $3.42 earnings per share. The firm's revenue was up 6.9% on a year-over-year basis.

BDX has been the topic of several other reports. Evercore ISI increased their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an "outperform" rating in a report on Tuesday, October 1st. Citigroup upgraded shares of Becton, Dickinson and Company from a "neutral" rating to a "buy" rating and upped their price objective for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Becton, Dickinson and Company presently has an average rating of "Buy" and a consensus price target of $283.50.

Becton, Dickinson and Company Trading Up 1.1 %

Shares of NYSE:BDX traded up $2.41 during mid-day trading on Wednesday, reaching $228.05. The stock had a trading volume of 1,225,208 shares, compared to its average volume of 1,469,390. The firm has a 50 day simple moving average of $230.57 and a two-hundred day simple moving average of $233.40. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $249.89. The firm has a market cap of $65.93 billion, a PE ratio of 37.99, a price-to-earnings-growth ratio of 1.64 and a beta of 0.41. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 9th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.82%. This is a positive change from Becton, Dickinson and Company's previous quarterly dividend of $0.95. The ex-dividend date of this dividend is Monday, December 9th. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 70.03%.

Insider Activity at Becton, Dickinson and Company

In other news, EVP Roland Goette sold 4,483 shares of the business's stock in a transaction on Friday, December 6th. The shares were sold at an average price of $221.01, for a total value of $990,787.83. Following the sale, the executive vice president now owns 24,345 shares of the company's stock, valued at $5,380,488.45. The trade was a 15.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.31% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Lord Abbett & CO. LLC increased its position in shares of Becton, Dickinson and Company by 0.5% during the 3rd quarter. Lord Abbett & CO. LLC now owns 195,858 shares of the medical instruments supplier's stock worth $47,221,000 after purchasing an additional 1,022 shares during the last quarter. Copley Financial Group Inc. bought a new position in shares of Becton, Dickinson and Company in the third quarter valued at $457,000. Oddo BHF Asset Management Sas acquired a new position in Becton, Dickinson and Company during the third quarter worth $522,000. Peapack Gladstone Financial Corp raised its position in Becton, Dickinson and Company by 2.1% during the third quarter. Peapack Gladstone Financial Corp now owns 101,600 shares of the medical instruments supplier's stock worth $24,497,000 after acquiring an additional 2,057 shares in the last quarter. Finally, Synovus Financial Corp lifted its stake in Becton, Dickinson and Company by 9.8% in the third quarter. Synovus Financial Corp now owns 9,017 shares of the medical instruments supplier's stock valued at $2,174,000 after acquiring an additional 808 shares during the last quarter. Institutional investors own 86.97% of the company's stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.